SCHEMBL6441301

SCHEMBL6441301

Cc1cccnc1COc1nc(N)nc(-n2cccn2)c1C#N

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.44
GABRA1 P14867 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA5 P31644 2/20 0.37
GABRA3 P34903 2/20 0.37
GABRA2 P47869 2/20 0.37
TLR7 Q9NYK1 4/20 0.36
KCNH2 Q12809 1/20 0.36
SQOR Q9Y6N5 3/20 0.36
ADORA1 P30542 4/20 0.35
NLRP3 Q96P20 2/20 0.32
GRM5 P41594 1/20 0.32
MBOAT4 Q96T53 1/20 0.32
ATP4A P20648 1/20 0.32
ATP4B P51164 1/20 0.32
ADORA2B P29275 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6442933 0.86 ADORA2A (0.42) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6441693 0.82 ADORA2A (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6441674 0.81 ADORA2A (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6442519 0.80 MGMT (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6444489 0.79 ADORA2A (0.40) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6467274 0.78 ADORA2A (0.44) ADORA2ASQORADORA1ATP4AATP4B
SCHEMBL6441954 0.77 ADORA2A (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6444568 0.77 ADORA2A (0.43) ADORA2ATLR7SQORADORA1NLRP3
SCHEMBL6443034 0.76 SQOR (0.41) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL5131727 0.73 ADORA2A (0.52) ADORA2ATLR7KCNH2SQORADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885GABRA1 64/4885GABRG2 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.